Morgan Stanley raises China Life Insurance's target price to 38.9 Hong Kong dollars and maintains an "overweight" rating.
The company's profits for the years 2026 to 2028 are estimated to be 0.1%, 0.3%, and 0.4% respectively.
Morgan Stanley released a research report stating that, considering the strong growth in new business value in the first quarter of China Life Insurance (02628), they have raised their relevant growth assumptions. As a result, the target price for China Life has been increased by 2.6% from HK$37.9 to HK$38.9, and the company's earnings forecast for 2026 to 2028 has been raised by 0.1%, 0.3%, and 0.4% respectively. Morgan Stanley continues to rate China Life as "overweight".
Related Articles
YOUZAN(06051) spent HK$1.5224 million on May 5th to repurchase 12 million shares.
Lingxiong Technology (02436) purchased 190,200 shares for HKD 3.0432 million on May 5.
JOHNSON HLDGS (01955) subsidiary secures HKD 230 million street cleaning services new contract with Food and Environmental Hygiene Department.
YOUZAN(06051) spent HK$1.5224 million on May 5th to repurchase 12 million shares.
Lingxiong Technology (02436) purchased 190,200 shares for HKD 3.0432 million on May 5.
JOHNSON HLDGS (01955) subsidiary secures HKD 230 million street cleaning services new contract with Food and Environmental Hygiene Department.
